{"id":2687,"date":"2014-12-29T10:20:15","date_gmt":"2014-12-29T10:20:15","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=2687"},"modified":"2014-12-27T10:20:31","modified_gmt":"2014-12-27T10:20:31","slug":"inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\/","title":{"rendered":"Inhibitoren des Renin-Angiotensin-Aldosteron-Systems in der Hochdrucktherapie"},"content":{"rendered":"<p>AMB 2012, 46, 52a Inhibitoren des Renin-Angiotensin-Aldosteron-Systems in der Hochdrucktherapie Inhibitoren des Renin-Angiotensin-Aldosteron-Systems (RAAS) werden im gro\u00dfen Ausma\u00df zur Behandlung der arteriellen Hypertonie eingesetzt. In einer systematischen Literaturrecherche identifizierten k\u00fcrzlich die Autoren einer Metaanalyse alle randomisierten kontrollierten Studien, in denen der Effekt von RAAS-Inhibitoren auf Morbidit\u00e4t und Letalit\u00e4t von Hypertonikern im Vergleich zu Plazebo, einer [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2012, 46, 52a Inhibitoren des Renin-Angiotensin-Aldosteron-Systems in der Hochdrucktherapie Inhibitoren des Renin-Angiotensin-Aldosteron-Systems (RAAS) werden im gro\u00dfen Ausma\u00df zur Behandlung der arteriellen Hypertonie eingesetzt. In einer systematischen Literaturrecherche identifizierten k\u00fcrzlich die Autoren einer Metaanalyse alle randomisierten kontrollierten Studien, in denen der Effekt von RAAS-Inhibitoren auf Morbidit\u00e4t und Letalit\u00e4t von Hypertonikern im Vergleich zu Plazebo, einer [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[954,75,76,338,339,67,77,340,1638,1639,1640,78,61,362,1641,79,1642,1643,74,1623,1644,1645,345,60,1646,1647,1286],"class_list":["post-2687","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-ace-hemmer","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-angiotensin-ii-rezeptor-antagonisten","tag-angiotensin-ii-rezeptor-blocker","tag-apoplektischer-insult","tag-arteriosklerose","tag-at-ii-blocker","tag-candesartan","tag-captopril","tag-enalapril-fosinopril","tag-herzinfarkt","tag-hirninfarkt","tag-hypertonie","tag-irbesartan","tag-koronare-herzkrankheit","tag-lisinopril","tag-losartan","tag-myokardinfarkt","tag-perindopril","tag-quinapril","tag-ramipril","tag-sartane","tag-schlaganfall","tag-telmisartan","tag-trandolapril","tag-valsartan"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Inhibitoren des Renin-Angiotensin-Aldosteron-Systems in der Hochdrucktherapie<\/title>\n<meta name=\"description\" content=\"Inhibitoren des Renin-Angiotensin-Aldosteron-Systems in der Hochdrucktherapie - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inhibitoren des Renin-Angiotensin-Aldosteron-Systems in der Hochdrucktherapie\" \/>\n<meta property=\"og:description\" content=\"Inhibitoren des Renin-Angiotensin-Aldosteron-Systems in der Hochdrucktherapie - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2014-12-29T10:20:15+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg\" \/>\n<meta name=\"author\" content=\"henk-amb\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"henk-amb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"5\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\\\/\"},\"author\":{\"name\":\"henk-amb\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"headline\":\"Inhibitoren des Renin-Angiotensin-Aldosteron-Systems in der Hochdrucktherapie\",\"datePublished\":\"2014-12-29T10:20:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\\\/\"},\"wordCount\":928,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"keywords\":[\"ACE-Hemmer\",\"Akutes Koronarsyndrom\",\"Angina pectoris\",\"Angiotensin-II-Rezeptor-Antagonisten\",\"Angiotensin-II-Rezeptor-Blocker\",\"Apoplektischer Insult\",\"Arteriosklerose\",\"AT-II-Blocker\",\"Candesartan\",\"Captopril\",\"Enalapril Fosinopril\",\"Herzinfarkt\",\"Hirninfarkt\",\"Hypertonie\",\"Irbesartan\",\"Koronare Herzkrankheit\",\"Lisinopril\",\"Losartan\",\"Myokardinfarkt\",\"Perindopril\",\"Quinapril\",\"Ramipril\",\"Sartane\",\"Schlaganfall\",\"Telmisartan\",\"Trandolapril\",\"Valsartan\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\\\/\",\"name\":\"Inhibitoren des Renin-Angiotensin-Aldosteron-Systems in der Hochdrucktherapie\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"datePublished\":\"2014-12-29T10:20:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"description\":\"Inhibitoren des Renin-Angiotensin-Aldosteron-Systems in der Hochdrucktherapie - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inhibitoren des Renin-Angiotensin-Aldosteron-Systems in der Hochdrucktherapie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\",\"name\":\"henk-amb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"caption\":\"henk-amb\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inhibitoren des Renin-Angiotensin-Aldosteron-Systems in der Hochdrucktherapie","description":"Inhibitoren des Renin-Angiotensin-Aldosteron-Systems in der Hochdrucktherapie - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\/","og_locale":"de_DE","og_type":"article","og_title":"Inhibitoren des Renin-Angiotensin-Aldosteron-Systems in der Hochdrucktherapie","og_description":"Inhibitoren des Renin-Angiotensin-Aldosteron-Systems in der Hochdrucktherapie - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2014-12-29T10:20:15+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","type":"","width":"","height":""}],"author":"henk-amb","twitter_misc":{"Verfasst von":"henk-amb","Gesch\u00e4tzte Lesezeit":"5\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\/"},"author":{"name":"henk-amb","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"headline":"Inhibitoren des Renin-Angiotensin-Aldosteron-Systems in der Hochdrucktherapie","datePublished":"2014-12-29T10:20:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\/"},"wordCount":928,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","keywords":["ACE-Hemmer","Akutes Koronarsyndrom","Angina pectoris","Angiotensin-II-Rezeptor-Antagonisten","Angiotensin-II-Rezeptor-Blocker","Apoplektischer Insult","Arteriosklerose","AT-II-Blocker","Candesartan","Captopril","Enalapril Fosinopril","Herzinfarkt","Hirninfarkt","Hypertonie","Irbesartan","Koronare Herzkrankheit","Lisinopril","Losartan","Myokardinfarkt","Perindopril","Quinapril","Ramipril","Sartane","Schlaganfall","Telmisartan","Trandolapril","Valsartan"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\/","name":"Inhibitoren des Renin-Angiotensin-Aldosteron-Systems in der Hochdrucktherapie","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","datePublished":"2014-12-29T10:20:15+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"description":"Inhibitoren des Renin-Angiotensin-Aldosteron-Systems in der Hochdrucktherapie - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/inhibitoren-des-renin-angiotensin-aldosteron-systems-in-der-hochdrucktherapie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Inhibitoren des Renin-Angiotensin-Aldosteron-Systems in der Hochdrucktherapie"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937","name":"henk-amb","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","caption":"henk-amb"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2687","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=2687"}],"version-history":[{"count":1,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2687\/revisions"}],"predecessor-version":[{"id":2688,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2687\/revisions\/2688"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=2687"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=2687"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=2687"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}